Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
January 29, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that JAAD published positive results from the pivotal Phase 3 STRATUM trial evaluating ZORYVE (roflumilast) foam, 0.3%.
Novan’s Phase 2 SB206 Molluscum Study Published in Journal of the American Academy of Dermatology
October 08, 2019 08:30 ET
|
Novan, Inc.
MORRISVILLE, N.C., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company’s Phase 2 molluscum study, designed to evaluate topical...